CoChat

SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy

Open access

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

Objective To delineate the epileptology, a key part of the SYNGAP1 phenotypic spectrum, in a large patient cohort. Methods Patients were recruited via investigators9 practices or social media. We included patients with (likely) pathogenic SYNGAP1 variants or chromosome 6p21.32 microdeletions incorporating SYNGAP1. We analyzed patients9 phenotypes using a standardized epilepsy questionnaire, medical records, EEG, MRI, and seizure videos. Results We included 57 patients (53% male, median age 8 years) with SYNGAP1 mutations (n = 53) or microdeletions (n = 4). Of the 57 patients, 56 had epilepsy: generalized in 55, with focal seizures in 7 and infantile spasms in 1. Median seizure onset age was 2 years. A novel type of drop attack was identified comprising eyelid myoclonia evolving to a myoclonic-atonic (n = 5) or atonic (n = 8) seizure. Seizure types included eyelid myoclonia with absences (65%), myoclonic seizures (34%), atypical (20%) and typical (18%) absences, and atonic seizures (14%), triggered by eating in 25%. Developmental delay preceded seizure onset in 54 of 56 (96%) patients for whom early developmental history was available. Developmental plateauing or regression occurred with seizures in 56 in the context of a developmental and epileptic encephalopathy (DEE). Fifty-five of 57 patients had intellectual disability, which was moderate to severe in 50. Other common features included behavioral problems (73%); high pain threshold (72%); eating problems, including oral aversion (68%); hypotonia (67%); sleeping problems (62%); autism spectrum disorder (54%); and ataxia or gait abnormalities (51%). Conclusions SYNGAP1 mutations cause a generalized DEE with a distinctive syndrome combining epilepsy with eyelid myoclonia with absences and myoclonic-atonic seizures, as well as a predilection to seizures triggered by eating.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000006729

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic presentation of SYNGAP1 mutations and microdeletions (A) in patients of our cohort or (B) previously published in the literature Chromosome 6p21.32 microdeletions including SYNGAP1, are presented as gray bars with << and >> indicating that their breakpoints were outside the region presented here. Truncating (◆) and splice-site (→) mutations are presented above the gene, and missense and in-frame (•) mutations are shown underneath the gene. Bold variants concern recurrent variants that were identified in our cohort but also previously published in the literature. Colors of the lines represent the epilepsy syndrome phenotype: moderate to severe developmental and epileptic encephalopathy (red), moderate to severe developmental encephalopathy with epilepsy (orange), moderate to severe developmental encephalopathy with no epilepsy (blue), mild developmental and epileptic encephalopathy (light green), mild developmental encephalopathy with no epilepsy (dark green), and unknown/unclassified epilepsy (gray). Chromosomal coordinates were based on National Center for Biotechnology Information Build 37 [hg19] and SYNGAP1 mutations, protein domains, and exons on the longest isoform 1 (NM_006772.2).
Figure 1 Schematic presentation of SYNGAP1 mutations and microdeletions (A) in patients of our cohort or (B) previously published in the literature Chromosome 6p21.32 microdeletions including SYNGAP1, are presented as gray bars with << and >> indicating that their breakpoints were outside the region presented here. Truncating (◆) and splice-site (→) mutations are presented above the gene, and missense and in-frame (•) mutations are shown underneath the gene. Bold variants concern recurrent variants that were identified in our cohort but also previously published in the literature. Colors of the lines represent the epilepsy syndrome phenotype: moderate to severe developmental and epileptic encephalopathy (red), moderate to severe developmental encephalopathy with epilepsy (orange), moderate to severe developmental encephalopathy with no epilepsy (blue), mild developmental and epileptic encephalopathy (light green), mild developmental encephalopathy with no epilepsy (dark green), and unknown/unclassified epilepsy (gray). Chromosomal coordinates were based on National Center for Biotechnology Information Build 37 [hg19] and SYNGAP1 mutations, protein domains, and exons on the longest isoform 1 (NM_006772.2).CC BY-NC-ND · PubMed Central
Figure 2 Ictal EEG registration during eyelid myoclonia–myoclonic–atonic seizure Red arrows indicate the different phases of the seizure associated with a generalized spike wave (eyelid myoclonia) and a further spike wave correlating with the myoclonic (spike) and atonic (wave) components.
Figure 2 Ictal EEG registration during eyelid myoclonia–myoclonic–atonic seizure Red arrows indicate the different phases of the seizure associated with a generalized spike wave (eyelid myoclonia) and a further spike wave correlating with the myoclonic (spike) and atonic (wave) components.CC BY-NC-ND · PubMed Central
Figure 3 SYNGAP1 dysmorphology Portrait photographs from 31 of 56 patients with SYNGAP1 mutations or microdeletions including SYNGAP1. (A) Patient 4, (B) patient 6, (C) patient 7, (D), patient 8 (sibling of patient 9), (E) patient 9 (sibling of patient 8), (F) patient 12, (G) patient 13, (H) patient 14, (I) patient 16, (J) patient 18, (K) patient 19, (L) patient 20, (M) patient 21, (N) patient 23, (O) patient 25, (P) patient 27, (Q) patient 28, (R) patient 29, (S) patient 31, (T) patient 32, (U) patient 33, (V) patient 34, (W) patient 35, (X) patient 37, (Y) patient 45, (Z) patient 47, (AA) patient 50, (AB) patient 51, (AC) patient 52, (AD) patient 54 (monozygotic twin with patient 55), and (AE) patient 55 (monozygotic twin with patient 54).
Figure 3 SYNGAP1 dysmorphology Portrait photographs from 31 of 56 patients with SYNGAP1 mutations or microdeletions including SYNGAP1. (A) Patient 4, (B) patient 6, (C) patient 7, (D), patient 8 (sibling of patient 9), (E) patient 9 (sibling of patient 8), (F) patient 12, (G) patient 13, (H) patient 14, (I) patient 16, (J) patient 18, (K) patient 19, (L) patient 20, (M) patient 21, (N) patient 23, (O) patient 25, (P) patient 27, (Q) patient 28, (R) patient 29, (S) patient 31, (T) patient 32, (U) patient 33, (V) patient 34, (W) patient 35, (X) patient 37, (Y) patient 45, (Z) patient 47, (AA) patient 50, (AB) patient 51, (AC) patient 52, (AD) patient 54 (monozygotic twin with patient 55), and (AE) patient 55 (monozygotic twin with patient 54).CC BY-NC-ND · PubMed Central
Figure 4 Brain pathology in a patient with an SYNGAP1 mutation (A) Glial fibrillary acidic protein (GFAP)–stained section of the cerebellar cortex showing a single surviving Purkinje cell (arrow points toward this cell) in a field of Purkinje cell loss and mild internal granular layer and cerebellar molecular layer astrocytosis. (B) GFAP staining of dentate gyrus showing no neuronal loss but mild reactive astrocytosis in the dentate granular layer and the dentate molecular layer of the hippocampus. (C) Vertex view of the cerebral hemispheres showing leptomeningeal fibrosis.
Figure 4 Brain pathology in a patient with an SYNGAP1 mutation (A) Glial fibrillary acidic protein (GFAP)–stained section of the cerebellar cortex showing a single surviving Purkinje cell (arrow points toward this cell) in a field of Purkinje cell loss and mild internal granular layer and cerebellar molecular layer astrocytosis. (B) GFAP staining of dentate gyrus showing no neuronal loss but mild reactive astrocytosis in the dentate granular layer and the dentate molecular layer of the hippocampus. (C) Vertex view of the cerebral hemispheres showing leptomeningeal fibrosis.CC BY-NC-ND · PubMed Central
Figure 5 SYNGAP1 encephalopathy This conceptual diagram highlights that the most common epilepsy phenotype in our cohort was an overlapping syndrome combining the features of 2 well-recognized epilepsy syndromes: epilepsy with eyelid myoclonia with absences (EMA) and epilepsy with myoclonic-atonic seizures (MAE). About one-third of the cohort did not fit into either of these syndromes and had nonsyndromic developmental and epileptic encephalopathy (DEE). One case had West syndrome. Other individuals with SYNGAP1 encephalopathy may have developmental encephalopathy (intellectual disability) without epilepsy.
Figure 5 SYNGAP1 encephalopathy This conceptual diagram highlights that the most common epilepsy phenotype in our cohort was an overlapping syndrome combining the features of 2 well-recognized epilepsy syndromes: epilepsy with eyelid myoclonia with absences (EMA) and epilepsy with myoclonic-atonic seizures (MAE). About one-third of the cohort did not fit into either of these syndromes and had nonsyndromic developmental and epileptic encephalopathy (DEE). One case had West syndrome. Other individuals with SYNGAP1 encephalopathy may have developmental encephalopathy (intellectual disability) without epilepsy.CC BY-NC-ND · PubMed Central
Figure 6 Comorbidities of SYNGAP1 encephalopathy The figure shows the percentage of each comorbidity associated with SYNGAP1 encephalopathy in our cohort. Dark red denotes moderate to severe intellectual disability; light red denotes mild intellectual disability.
Figure 6 Comorbidities of SYNGAP1 encephalopathy The figure shows the percentage of each comorbidity associated with SYNGAP1 encephalopathy in our cohort. Dark red denotes moderate to severe intellectual disability; light red denotes mild intellectual disability.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 1

  1. Fisher RS , Cross JH , French JA , et al . Operational classification of seizure types by the International League Against Epilepsy [online serial]. Epilepsia 2017:1–9. Available at: ilae.org. Accessed January 17, 2018.

Cited by

See all 238

Metadata

Authors
Vlaskamp, D. R. M., Shaw, B. J., Burgess, R., Mei, D., Montomoli, M., Xie, H., Myers, C. T., Bennett, M. F., XiangWei, W., Williams, D., Maas, S. M., Brooks, A. S., Mancini, G. M. S., van de Laar, I. M. B. H., van Hagen, J. M., Ware, T. L., Webster, R. I., Malone, S., Berkovic, S. F., Kalnins, R. M., Sicca, F., Korenke, G. C., van Ravenswaaij-Arts, C. M. A., Hildebrand, M. S., Mefford, H. C., Jiang, Y., Guerrini, R., & Scheffer, I. E.
Affiliations
  • University Medical Center Groningen (NL)
  • From the Epilepsy Research Centre (D.R.M.V., B.J.S., R.B., M.F.B., S.F.B., M.S.H., I.E.S.), Department of Medicine, University of Melbourne, Austin Health, Australia; Departments of Genetics (D.R.M.V., C.M.A.v.R.-A.) and Neurology (D.R.M.V.), University Medical Center Groningen, University of Groningen, the Netherlands; Pediatric Neurology Unit and Laboratories (D.M., M.M.) and Pediatric Neurology (R.G.), Neurogenetics and Neurobiology Unit and Laboratories, A. Meyer Children's Hospital, University...
Corresponding author
Scheffer, Ingrid E.
Venue
Neurology
Published
2019-01-08
Volume
92
Issue
2
Pages
e96-e107
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2904696555
Cited by
206
References
50
Citations by year
2026: 20 · 2025: 32 · 2024: 39 · 2023: 27 · 2022: 21 · 2021: 30 · 2020: 27 · 2019: 7
FWCI
12.89
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Neurology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by-nc-nd)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-nd)
Funders
  • U.S. Department of Defense
  • March of Dimes Foundation
  • Citizens United for Research in Epilepsy
  • Fondazione Pisa
  • Zogenix
  • GW Pharmaceuticals
  • Australian Government
  • European Commission (602531)
  • National Natural Science Foundation of China (2016‐2020, 81501123)
  • Ministero della Salute
  • Eisai
  • Fondazione Pierfranco e Luisa Mariani
  • Regione Toscana
  • National Institutes of Health
  • Medical Research Council
  • National Health and Medical Research Council (1091593, 1104831)
  • Health Research Council of New Zealand
  • National Institute of Neurological Disorders and Stroke (R01NS069605)
  • UCB Pharma
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
Keywords
SYNGAP1, developmental and epileptic encephalopathy, epileptology, eyelid myoclonia with absences, myoclonic-atonic seizures, atonic seizures, intellectual disability, autism spectrum disorder, developmental delay, behavioral problems
MeSH terms
Adolescent, Adult, Anticonvulsants, Brain, Brain Diseases, Child, Developmental Disabilities, Child, Preschool, Electroencephalography, Female, Humans, Infant, Male, Mutation, Spasms, Infantile, Cohort Studies, ras GTPase-Activating Proteins, Young Adult, Genetic Association Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy. https://app.cochat.ai/papers/10.1212/wnl.0000000000006729
The paper
Vlaskamp, D. R. M., Shaw, B. J., Burgess, R., Mei, D., Montomoli, M., Xie, H., Myers, C. T., Bennett, M. F., XiangWei, W., Williams, D., Maas, S. M., Brooks, A. S., Mancini, G. M. S., van de Laar, I. M. B. H., van Hagen, J. M., Ware, T. L., Webster, R. I., Malone, S., Berkovic, S. F., . . . Scheffer, I. E. (2019). SYNGAP1 encephalopathy: A distinctive generalized developmental and epileptic encephalopathy. Neurology. https://doi.org/10.1212/wnl.0000000000006729

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.